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Background: Multiple sclerosis (MS) is a chronic disease that affects mainly adults in the prime of their lives.
However, few studies report the impact of high annual relapse rates on outcomes. The purpose of this study was to
identify high relapse activity (HRA) in patients with MS, comparing differences in outcomes between patients with
and without HRA.
Methods: A retrospective longitudinal study was conducted using the MarketScanW Commercial Claims and
Encounters and Medicare Supplemental Database. Patients had to have at least one ICD-9 for MS (340.XX) in 2009
and one in 2008, be older than 18 years, and have continuous enrolment in the years 2009–2010. HRA was defined
as having ≥2 relapses in 2009. Multivariate analyses compared all-cause and MS-specific emergency room (ER) visits,
hospitalizations, and all-cause costs, excluding disease modifying therapy (DMT) costs, in 2010 between patients
with and without HRA, controlling for baseline characteristics. A subgroup analysis using treatment exposure was
also performed.
Results: 19,219 patients were included: 5.3% (n=1,017) had ≥2 relapses in 2009. Patients with HRA were more likely
to have all-cause and MS-specific resource utilization than patients without HRA. Mean total all-cause non DMT
costs were $12,057 higher for the HRA group. In the subgroup analysis, HRA treatment-naïve patients were more
likely to start treatment, and HRA treatment-experienced patients were more likely to discontinue or switch index
DMT (P<0.01).
Conclusions: Patients with ≥2 relapses annually have higher resource utilization and costs. The difference in cost
was over twice as large in treatment-naïve patients versus treatment-experienced patients. HRA was also associated
with an increased likelihood of starting DMT treatment (treatment-naïve patients), and switching or discontinuing
DMT therapy (treatment-experienced patients).Background
Relapsing remitting multiple sclerosis (RRMS) is charac-
terized by relapses interspersed between periods of remis-
sion. Relapses can last for days, weeks, or months, and
cause significant disability and distress [1,2]. Symptoms of
multiple sclerosis (MS) include fatigue, spasticity, sensory* Correspondence: karina.pupio@gmail.com
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distribution, and reproduction in any mediumdisturbances, pain, ataxia, tremor, bladder and bowel is-
sues, cognitive effects, weakness, and depression, which
affect daily functioning and impact quality of life [2,3].
Furthermore, a strong correlation has been reported be-
tween the frequency of relapses and long-term disability,
with increased number of relapses early in the course of
disease associated with a greater risk of expanded disabil-
ity status scale (EDSS) worsening over time [4].
Given the clinical presentation of MS, the disease can
result in a substantial economic burden. Direct and in-
direct costs associated with MS in the United States
(US) have been estimated at approximately $2.5 billion
[5], and because the prevalence of MS appears to betral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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The total average direct cost of treatment was found to
be $47,215 per patient per year (2004 US dollars) [7].
Because disease presentation can vary widely among pa-
tients, costs can be significantly different depending on
disease severity and frequency of relapses requiring
intervention [5]. Treatment costs rise with increasingly
complex treatments for individual relapses; treatment
complexity is often related to the severity of the relapse.
For patients with relapses requiring minimal manage-
ment (physician visits and symptom-related medication
only), the total cost was $243 per episode (2002 US dol-
lars); for relapses requiring moderate intervention (acute
hospital, qualifying corticosteroid medication, outpatient
follow-up and physical, occupational or speech therapy),
the total cost was $1,847 per episode; however, for those
requiring a high level of management (acute hospital,
post-discharge, rehabilitation facility, skilled nursing fa-
cility, short-term nursing home, home healthcare ser-
vices, and outpatient care), costs rose to $12,870 per
episode [5].
Early studies have established a general frequency of
relapses of 0.1 to 1.2 per year [8]. We hypothesized that
patients with higher frequencies of relapses in a given
year would be significantly more costly and use more re-
sources in the following year. The rationale for this hy-
pothesis is that relapse activity is mediated by central
nervous system (CNS) inflammatory activity [9]. There-
fore, high relapse activity (HRA) may indicate a more re-
fractory or complex form of MS that requires more
involved and costly interventions. The objective of this
study was to identify and compare resource utilization
and costs between patients with and without HRA. In
addition, this study aimed to investigate the differences
in treatment patterns and costs between patients with




This was a retrospective, cohort study using MarketScanW
Commercial Claims and Encounters Database (CCAE)
and the Medicare Supplemental and Coordination of Ben-
efits Database (Medicare Supplement) [10]. The CCAE
database represents the healthcare experience of enrolees
in commercial health insurance plans sponsored by >100
large-sized and medium-sized employers in the US, which
includes monthly enrolment data, inpatient and outpatient
medical claims, outpatient prescription drug claims, and
eligibility information. The Medicare Supplement includes
inpatient and outpatient Medicare supplemental medical
claims, linked to drug, person-level enrolment, and benefit
plan design data for retirees covered by their previous em-
ployers. Both the employer-paid and Medicare-paidcomponents of care are represented in the database.
These databases include the health services of em-
ployees, dependents, and retirees in the US with pri-
mary or Medicare supplemental coverage through
privately insured fee-for-service (FFS), point-of-service
(POS), or capitated health plans, and are generally rep-
resentative of the population in the US in terms of
gender and age. Because all study data were accessed
using techniques compliant with the Health Insurance
Portability and Accountability Act, of 1996, informed
consent or institutional review board approval was not
sought. Novartis Pharmaceuticals Corporation licenses
MarketScan Commercial and Medicare databases, and
therefore has the right to analyze, interpret, and pub-
lish the findings obtained from the dataset.
Patient populations
Main analysis
Patients had to have at least one International Classifica-
tion of Diseases (ICD)-9-Clinical Modification (CM) for
MS (340.XX) in 2009 and one in the prior year, had con-
tinuous enrolment in the year of 2009 and 2010, and be
18 years or older in 2009 (Figure 1). Patients were di-
vided into two cohorts: patients with HRA (HRA cohort)
who had two or more relapses during 2009, and patients
without HRA (non-HRA cohort) who had 0 or 1 relapse
during 2009. Relapse was defined according to a vali-
dated claims-based relapse detection algorithm [11,12].
The algorithm defined relapses as either: 1) a claim with
an MS diagnosis code in the primary position at any
time during an inpatient hospitalization, or 2) a claim
with an MS diagnosis code in the primary or secondary
position in an outpatient setting (including ER visits) in
addition to a pharmacy or medical claim for a qualifying
corticosteroid on the day of or within 7 days after the
visit. A “clean period” of 30 days with none of the events
described above was required between the start of separ-
ate relapses; otherwise, such claims were incorporated
into a single-relapse event.
Subgroup definition – treatment-naïve and treatment-
experienced
In addition, we performed a subgroup analysis of
treatment-naïve and treatment-experienced patients.
Patients with no DMT treatment in 2009 were classi-
fied as treatment-naïve, while those whose proportion
of days covered (PDC) value for any DMT was ≥80%
in 2009 were considered treatment-experienced. PDC
was calculated as the number of days with drug avail-
able divided by the number of days in 2009. The 80%
PDC threshold was chosen to ensure that discontinu-
ation or switching treatment, which requires a 60-day
gap, would occur in the follow-up period (2010). A
PDC ≥80% is generally an adequate threshold to be
Patients with ≥ 1 ICD-9-CM: 340.xx diagnosis in 2009a
(N=57,678)
Patients ≥ 18 years old
(n=19,219)
Patients with ≥ 1 ICD-9-CM: 340.xx diagnosis in 2008a
(N=29,290)
Patients continuously enrolled in
medical and pharmacy benefit in 2009 and 2010 
(n=19,247)
Treatment-naïve Cohort:




Patients whose PDC value for any 





Figure 1 Patient selection flowchart. ICD=International Classification of Diseases; CM=Clinical Modification; DMT=disease modifying therapy;
PDC=proportion of days covered. aNon rule out diagnosis was used to define patients. bInterferon β-1a, interferon β-1b, glatiramer acetate,
or natalizumab.
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fects of variables on treatment decisions [13]. Few pa-
tients using ABCR (Avonex, Betaseron, Copaxone, and
Rebif ) were billed through J-codes (in-office adminis-
tration of injectable therapies), and were excluded
from the treatment-experienced cohort since these
codes are linked to generic names and only indicate
standard dosages, thereby not allowing us to differenti-
ate between different DMT dosages or administration
mode or identify treatment switches. The majority of the
injectable therapies in this study are dispensed through
pharmacies which were captured using National Drug
Code (NDC) claims. Therapies administered in office, and
captured using J-codes, such as natalizumab, were also in-
cluded in the analysis.
Statistical analysis
Main analysis
Bivariate descriptive statistics compared baseline charac-
teristics of the HRA and non-HRA cohorts with respect
to demographics (age, sex, and geographic location),
comorbidities, resource utilization, and costs (excluding
DMTs) using t-tests for continuous variables, and Chi-
square tests for categorical variables. Multivariate analyses
were performed using longitudinal logistic regression
models to compare all-cause and MS-specific ER visits
and hospitalizations, controlling for age, gender, geo-
graphic region, health plan type, employment status,
Charlson comorbidity index (CCI), presence of MS symp-
toms [3], all-cause ER visits and all-cause hospitalization.
All-cause non-DMT costs in 2010 between patients withHRA and those without HRA were compared using a
gamma regression with log link model, controlling for the
same variables mentioned above. The adjusted costs were
predicted for patients with and without and HRA and the
cost differences were calculated accordingly. The standard
errors and 95% confidence intervals (CI) were provided
using paired bootstrapping technique with bias-corrected
method [14].
Subgroup analysis
Multivariate analysis was performed to compare patients
with HRA and those without HRA for the likelihood of
starting treatment (naïve cohort), or switching and discon-
tinuing treatment (treatment-experienced cohort) using
longitudinal logistic regression models, controlling for
age, gender, geographic region, health plan type, employ-
ment status, CCI, presence of MS symptoms [3], all-cause
ER visits and all-cause hospitalization. Comparisons of all-
cause costs (non-DMT costs) were also performed using a
gamma regression with log link model in 2010 between
patients with HRA and those without HRA, controlling
for the same variables mentioned above. Sensitivity ana-
lysis was performed for the treatment-experienced cohort
to include all patients treated with DMT at some point in
2009, regardless of their PDC to test the impact of the
treatment-experience cohort selection criteria on the re-
sults. Given that there were no time constraints to the def-
inition of exposure, patients could have had the exposure
to DMT and outcome (start, switch or discontinue index
DMT treatment) within the same year; thus, a flexible
follow-up period censored on Dec 31, 2010 was used.
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A total of 19,219 patients met the study criteria; 94.7%
(n=18,202) had less than two relapses and 5.3% (n=1,017)
had two or more relapses in 2009 (Table 1). Patients with
HRA and those without HRA differed in several charac-
teristics. The HRA cohort was younger (mean age 49.5 vs.Table 1 Bivariate analyses for baseline characteristics (year 2
Variable Non-HRA cohorta (n=18,20
Age Group, mean (SD) 51.6 (11.1)









Geographic Region, n (%)
North East 2,294 (12.6)




Employment Status, n (%)
Employees 10,279 (56.5)
Spouse/Child/Other 7,923 (43.5)
Insurance Type, n (%)
Fee for Service (FFS) 14,800 (81.3)
Non-FFS 2,976 (16.4)
Missing 426 (2.3)
CCI, mean (SD) 0.6 (1.1)
Any MS Symptoms, n (%)d
Yes 12,513 (68.8)
No 5,689 (31.3)









MS=multiple sclerosis; SD=standard deviation; FFS=fee for service; CCI=Charlson Co
aNon-HRA cohort: MS relapse equal to 0 or 1 in year 2009.
bHRA cohort: MS relapse ≥2 in year 2009.
cP values of overall comparison: Chi-square for categorical variables; t-test for contin
dIncluding the following list from the National Multiple Sclerosis Society: fatigue, nu
bowel dysfunction, visual symptoms, sexual dysfunction, dizziness and vertigo, pain
emotional changes, speech disorders, swallowing problems, headache, hearing loss51.6 years) and less likely to be employed (50.2% vs.
56.5%) than the non-HRA cohort (P<0.0001 for both). The
mean CCI was 0.8 for patients with HRA versus 0.6
for patients without HRA (P<0.0001). Patients with
HRA reported a higher number of MS symptoms
and DMT use in 2009. Patients with HRA had more009)





































morbidity Index; DMT=disease modifying therapy; ER=emergency room.
uous variables.
mbness, walking (gait), balance, & coordination problems, bladder dysfunction,
, muscle weakness/spasm/spasticity, cognitive function, depression and other
, seizures, tremors, respiration/breathing problems, and itching.
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tions in 2009 (P<0.0001 for all).
After adjusting for baseline characteristics, patients
in the HRA cohort were more likely to have all-cause
and MS-specific ER visits and hospitalizations in the
following year (Table 2). The presence of MS symp-
toms and all-cause ER visits or hospitalizations in the
prior-period were associated with an increased likeli-
hood of ER visit or hospitalization during the follow-
up period.
Costs
Table 3 shows the adjusted mean total annual all-cause
costs (excluding DMT costs) for patients with HRA in the
follow-up year was $26,803 (95% CI: $24,479-$28,794)
compared with $14,745 (95% CI: $14,365-$15,141) for pa-
tients without HRA group for a cost difference of $12,057
(95% CI: $9,717-$14,074).
Subgroup analysis
The subgroup analysis identified 6,042 patients who
were DMT naïve and 13,177 who had prior DMT expos-
ure. Among the prior DMT users, 12,954 patients were
eligible for the study (excluding patients with J-codes)Table 2 Adjusted all-cause or MS-specific ER and hospitalizati
Variablea All-cause ER visits All-cause ho
MS Relapse ≥2 1.33 (1.15-1.54)b 1.97 (1
Age group
(36–45, Ref: 18–35) 0.81 (0.70-0.93)c 0.66 (0
(46–55, Ref: 18–35) 0.75 (0.65-0.85)b 0.79 (0
(56–65, Ref: 18–35) 0.83 (0.72-0.95)c 1.02 (0
(65+, Ref: 18–35) 1.12 (0.95-1.32) 1.70 (1
Female (Ref: male) 1.10 (1.01-1.20)c 0.95 (0
Region
North Central (Ref: Northeast) 1.16 (1.03-1.30)c 1.09 (0
South (Ref: Northeast) 1.03 (0.91-1.16) 1.01 (0
West (Ref: Northeast) 0.95 (0.84-1.08) 0.93 (0
Unknown (Ref: Northeast) 1.63 (0.54-4.92) 1.04 (0
Non-Employee (Ref: Employee) 1.07 (1.00-1.15) 1.06 (0
Plan type
HMO and POS capitation (Ref: FFS) 0.94 (0.85-1.04) 0.93 (0
Missing (Ref: FFS) 0.76 (0.59-0.98) 0.79 (0
CCI 1.13 (1.10-1.16)b 1.21 (1
Any MS symptoms 1.53 (1.40-1.67)b 1.47 (1
Any DMT use 0.87 (0.80-0.94)c 0.79 (0
All-cause ER visits 2.50 (2.31-2.71)b 1.75 (1
All-cause hospitalizations 1.37 (1.24-1.52)b 2.43 (2
MS=multiple sclerosis; Ref=reference; HMO=health maintenance organization; POS=
DMTs=disease modifying therapy; ER=emergency room.
aVariables were from 2009 and outcomes measured in 2010.
bAll tests were statistically significant at P<0.0001, cP<0.05; and dP<0.001.and had exposure to DMT in the year 2009; of which,
6,923 (53%) patients had PDC ≥80% and were classified
as treatment-experienced (Figure 1). Among treatment-
naïve patients, those with HRA were more likely to start
DMT use than those without HRA in the follow-up
period [odd ratio (OR) 1.56, 95% CI: 1.08-2.23; Figure 2].
Among treatment-experienced patients (PDC ≥80%), HRA
was associated with a greater likelihood of discontinuing
the index DMT (OR=1.75, 95% CI: 1.35-2.26) or switching
from the index DMT to another DMT (OR=2.74, 95% CI:
1.89-3.99) than patients without HRA in the follow-up
period (Figure 2).
Excluding DMT-related costs, total healthcare costs
for 2010 for this subgroup analysis of treatment-naïve
and treatment-experienced populations were similar to
the overall group in that patients with HRA had higher
costs than those without HRA. In the treatment-naïve
cohort, costs were $33,855.63 (95% CI: $28,050.17-
$40,945.48) in those with HRA versus $18,100.61 (95%
CI: $17,260.92-$18,994.27), for a cost difference of
$15,755.03 (95% CI: $9,321.56-$22,770.56; data not
shown). In the treatment-experienced cohort, costs
were $19,849.38 (95% CI: $17,624.66-$22,317.70) in those
with HRA and $12,243.92 (95% CI: $11,767.29-$12,798.37)on visits
spitalizations MS-specific ER visits MS-specific hospitalizations
.67-2.32)b 1.72 (1.43-2.08)b 3.25 (2.47-4.29)b
.54-0.80)b 0.82 (0.67-1.01) 1.20 (0.79-1.83)
.66-0.94)c 0.70 (0.58-0.85)d 0.95 (0.63-1.43)
.86-1.22) 0.70 (0.58-0.85)d 0.82 (0.54-1.25)
.38-2.08)b 0.71 (0.55-0.90)c 0.92 (0.55-1.52)
.85-1.06) 1.07 (0.93-1.22) 0.87 (0.68-1.12)
.94-1.27) 1.60 (1.32-1.95)b 1.24 (0.88-1.76)
.87-1.18) 1.33 (1.09-1.62)c 0.97 (0.68-1.38)
.78-1.10) 1.64 (1.33-2.02)b 0.82 (0.54-1.22)
.22-4.85) 1.08 (0.14-8.55) 7.77 (1.57-38.53)c
.97-1.17) 1.12 (1.00-1.25)c 1.35 (1.09-1.67)c
.81-1.06) 1.13 (0.98-1.30) 0.80 (0.58-1.11)
.57-1.11) 0.91 (0.63-1.32) 0.67 (0.27-1.65)
.17-1.25)b 1.04 (1.0-1.09) 1.09 (1.01-1.17)c
.30-1.66)b 1.56 (1.36-1.80)b 1.70 (1.24-2.33)c
.72-0.87)b 0.96 (0.85-1.07) 1.24 (0.98-1.57)
.58-1.94)b 2.33 (2.07-2.62)b 1.86 (1.47-2.35)b
.16-2.73)b 1.46 (1.27-1.69)b 3.12 (2.43-4.01)b
point of service; FFS=fee for service; CCI=Charlson Comorbidity Index;
Table 3 Adjusted mean total all-cause costs (excluding







HRA group $26,803.19 $1126.41 $24,478.92 $28,793.61
Non-HRA group $14,745.85 $211.09 $14,365.36 $15,140.86
Cost difference 12,057.34 $1149.85 $9,716.94 $14,073.66
aBootstrapping: repeat 200; bias correction method.
HRA=high relapse activity; CI=confidence interval.
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(95% CI: $5,281.50-$10,096.58; data not shown).Sensitivity analysis
The sensitivity analysis included all patients with expos-
ure to DMT in 2009, regardless of their PDC, in the
treatment-experienced cohort. We identified 12,954 eli-
gible patients, of which 748 (5.8%) had HRA. Patients
with HRA were more likely to discontinue their DMT
before Dec 31, 2010 (OR: 1.47, 95% CI: 1.26-1.71), or
switch from the index DMT to another DMT before
Dec 31, 2010 (OR=2.41, 95% CI: 1.90-3.06) than patients
without HRA (data not shown).
Excluding DMT-related costs, total differences in
healthcare costs for 2010 for the experienced subgroup
sensitivity analysis was larger than the treatment-
experienced cohort in the main analysis. Total costs
were $23,573.50 (95% CI: $21,579.51- $25,799.29) in
those with HRA and $13,140.34 (95% CI: $12,600.33-
$13,546.19) in those without HRA, for a cost difference
of $10,433.16 (95% CI: $8,545.54-$12,735.78; data not
shown).Discussion
Main analysis
This retrospective claims database study showed that pa-
tients with MS and HRA have greater resource utilizationFigure 2 Likelihood of starting, switching or discontinuing DMT treat
index DMT treatment refers to the last DMT treatment in the year 2009.and costs than patients without HRA. The likelihood of
all-cause and MS-specific ER visits and hospitalizations
was significantly greater for patients with HRA than for
those without HRA. Because relapse frequency changes
slowly over time, all-cause and MS-specific ER visits and
hospitalizations in 2009 increased the likelihood of similar
visits in 2010. Patients with HRA were younger than those
with fewer relapses, consistent with previous reports that
have shown that relapse frequency diminishes over time
[15]. The direct annual non-DMT cost of patients with
MS and HRA was $12,057 greater than patients without
HRA. These results were expected given that more fre-
quent relapses likely indicate a more complex, refractory
disease course that may require more involved manage-
ment, including costly hospitalizations. In this regard,
HRA may reflect an underlying pathology rather than a
state of MS characterized by ongoing CNS inflammation
despite clinical management. A previous retrospective
study of a managed care medical and pharmacy claims
database found that patients with no relapses cost an an-
nual average of $6007 (1995–96 US dollars) while those
who experienced two relapses had total costs of $14,521,
and those with more than two relapses had costs totaling
$20,519 [16].Subgroup analysis
Disease modifying treatments are important tools for the
management of MS, reducing relapse frequency and ac-
cumulation of irreversible disability. However, patients
may have suboptimal responses to first-line therapy,
prompting a switch to a different DMT or discontinu-
ation of all therapy [17]. Our subgroup analysis found
that treatment-naïve patients with HRA were more likely
to start DMT treatment, while treatment-experienced
patients with HRA were more likely to switch or discon-
tinue DMT therapy. Our sensitivity analysis showed that
using a less conservative definition of treatment-
experience, where all patients with DMT use in yearment for patients with HRA. DMT=disease modifying therapy. *The
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PDC, yielded similar results. The small reduction in the
sensitivity analysis is explained by the fact that patients
could have started and switched or discontinued their
DMT treatment in the same year (2009), while in the
main treatment-experienced cohort, we were able to
identify patients who switched or discontinued in the
follow-up year (2010) only. The latter is a more precise
approach since we are able to separate exposure to the
outcome that was being predicted.
The results of the subanalysis are compatible with the
work of Visser et al. (2011) [18] that found that 66% of
patients who switched DMTs cited progression of dis-
ease as the reason for the switch, while 53% of those
who discontinued DMT treatment indicated that uncer-
tainty about efficacy had a “very big influence” or a “big
influence” on why they discontinued DMT [18]. What is
striking in our study is that, despite a higher probability
of treatment switching, HRA patients continued to have
high costs in the subsequent year. This suggests that
switching among existing DMTs may not be effective in
managing relapse activity. A study by Prosperini et al. (2012)
[19] indicated that switching among self-injectable DMTs
was not associated with benefits, but escalation to a different
mechanism of action with higher potency did increase the
duration of disease-free activity [19]. Additional studies with
more recent data are needed to examine the differential
effect of high-efficacy options such as fingolimod and
natalizumab on reducing costs among patients with HRA.
Limitations
There are a few limitations to be acknowledged in this
study. The first limitation of this analysis is that there is
no known HRA definition; however, the authors believed
that having 2 or more relapses a year is more than the
estimated yearly rates of 0.2 to 1.2 [8]. In addition, the
definitions of MS relapse and thresholds for intervention
may vary among clinicians, and the algorithm used to
identify relapses was based on the treatments received.
Therefore, the true number of relapses may be
underestimated. The present investigation into costs as-
sociated with relapses did not include DMTs because
their use is not restricted to the time of relapse and are
instead, used on a continued basis for long-term man-
agement. The costs of DMTs contribute substantially to
the total costs of managing MS, and the objective of the
current study was to assess medical costs, which are a
proxy for ongoing disease activity, that generate non-
drug costs, as well as lowered quality of life and in-
creased risk for accumulation of irreversible disability;
however, this was out of the scope of this work. Finally,
resource utilization and costs were evaluated over a one-
year follow-up period; a longer time horizon may be ne-
cessary to assess long-term outcomes and costs.Conclusions
This analysis shows that patients with two or more re-
lapses in a given year have higher resource utilization
and are more costly in the following year than those
with less than two relapses. HRA predicts DMT initi-
ation among treatment-naïve patients, and switching or
discontinuation DMT among treatment-experienced pa-
tients. Future research should investigate the effects of
relapse activity on long-term costs.
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